CBD Meds, Inc.
Agreed to an FTC consent order over allegedly unsupported claims that CBD treats cancer and glaucoma
This entry is about the United States — not the country you picked in the header.
According to Federal Trade Commission, Dec 17, 2020 · Read the source · +1 more
- Where
- California, United States
- First reported
- Last checked
Resolved or closed
The source lists this matter as resolved or closed. The entry stays public so the record remains available.
Summary
CBD Meds, Inc. and G2 Hemp, Inc., firms based in Winchester, California, were named in the FTC's December 2020 enforcement sweep against deceptive CBD marketing, known as Operation CBDeceit. According to the FTC, the companies promoted CBD oil on their website and on YouTube with false or unsubstantiated claims that it could treat or prevent serious conditions, among them cancer and glaucoma. Together with their principal, the companies agreed to an administrative consent order that the FTC finalized on March 5, 2021. The order prohibits them from claiming that a product prevents or treats disease unless human clinical testing supports it, requires competent scientific evidence for other health claims, and obliges them to tell customers about the order. Unlike most other companies in the sweep, no monetary payment is listed for this matter in the FTC's announcement. The case is marked closed on the FTC website.
What the source found
- The FTC alleged false or unsubstantiated claims that CBD could treat serious diseases, including cancer and glaucoma.
- According to the FTC, the claims appeared on the companies' website and on YouTube.
- The consent order bars disease claims without human clinical testing and requires notice to consumers.
Products named
- CBD oil
Timeline
FTC announces administrative complaint and proposed consent order
FTC approves final decision and order; case closed
Sources
- Regulator
Federal Trade Commission · Dec 17, 2020
FTC Announces Crackdown on Deceptively Marketed CBD Products - Regulator
Federal Trade Commission · Mar 5, 2021
CBD Meds, Inc., In the Matter of
Wording on this page follows the sources. Found an error? See the corrections process in our editorial policy.
Status notes
Settled through an administrative consent order in 2021; the FTC lists the case as closed. The order's restrictions on health claims remain in force. Current trading status of the business was not verified.
Comments
No comments yet.
Related entries
The full Red ListHerbal Pathways, LLC d/b/a HiBrid
HiBrid
Massachusetts regulator order over sales of products with out-of-date test results in Pittsfield
Empire 1 Convenience CORP
Empire 1 Convenience CORP
NYC Sheriff summons for a cannabis violation by a place of business
Purple Sky 1 CORP
Purple Sky 1 CORP
NYC Sheriff summons for a cannabis violation by a place of business
Tell us what happened
Every report is read by a person. You don’t need to prove anything, and we never publish your name.
- A moderator reads your report and checks the link against the Red List and our seller records.
- We look for an authoritative source — a regulator, court, police or consumer-protection finding.
- When a source confirms it, your report is linked to a Red List entry. Your name and contact details stay private.